Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma

PHASE1TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

October 29, 2018

Primary Completion Date

January 12, 2022

Study Completion Date

January 12, 2022

Conditions
Diffuse Large B-cell Lymphoma(DLBCL)Mantle Cell Lymphoma (MCL)Follicular Lymphoma (FL)
Interventions
DRUG

AMG 562

AMG 562 is a BiTE® antibody construct that targets CD19 and is intended for the treatment of patients with B-cell malignancies.

Trial Locations (12)

3000

Universitair Ziekenhuis Leuven - Campus Gasthuisberg, Leuven

14263

Roswell Park Cancer Institute, Buffalo

21201

University of Maryland Greenebaum Cancer Center, Baltimore

27157

Wake Forest Baptist Health, Winston-Salem

44106

University Hospitals Cleveland Medical Center, Cleveland

63110

Washington University, St Louis

81377

Klinikum der Universität München Campus Großhadern, München

89081

Universitatsklinikum Ulm, Ulm

90095

University of California Los Angeles, Los Angeles

91010

City of Hope National Medical Center, Duarte

97080

Universitätsklinikum Würzburg, Würzburg

M5G 2M9

Princess Margaret Cancer Centre, Toronto

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY